Hypofractionated radiotherapy in prostate cancer

Affiliations

Comment

David P Dearnaley. Lancet Oncol. 2015 Mar.

. 2015 Mar;16(3):237-8.

doi: 10.1016/S1470-2045(15)70021-5. Epub 2015 Feb 3.

¹ Division of Radiotherapy and Imaging, The Institute of Cancer Research, London SM2 5NG, UK. Electronic address: David.Dearnaley@icr.ac.uk.

Erratum in

Correction to Lancet Oncol 2015; 16: 237.
Dearnaley DP. Dearnaley DP. Lancet Oncol. 2015 Mar;16(3):e105. doi: 10.1016/S1470-2045(15)70097-5. Lancet Oncol. 2015. PMID: 25752561 No abstract available.

No abstract available

Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial.
Aluwini S, Pos F, Schimmel E, van Lin E, Krol S, van der Toorn PP, de Jager H, Dirkx M, Alemayehu WG, Heijmen B, Incrocci L. Aluwini S, et al. Lancet Oncol. 2015 Mar;16(3):274-83. doi: 10.1016/S1470-2045(14)70482-6. Epub 2015 Feb 3. Lancet Oncol. 2015. PMID: 25656287 Clinical Trial.